Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1

Interventions

Oxaliplatin 180Capecitabine 174Fluorouracil 154Radiotherapy 107Leucovorin 107Irinotecan 93Bevacizumab 69Surgical Procedures, Operative 49Cetuximab 39Drug Therapy 38Radiation 35Neoadjuvant Therapy 33Folfox protocol 29Chemoradiotherapy 29XELOX 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 21Radiotherapy, Intensity-Modulated 19Surveys and Questionnaires 17Proctectomy 16Biopsy 16Early Intervention, Educational 14trifluridine tipiracil drug combination 12Panitumumab 12Floxuridine 12tislelizumab 11regorafenib 11Nivolumab 11Laparoscopy 11Celecoxib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rectal Neoplasms × CB-839 × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡